So why is Alex­ion pay­ing $100M for a PRV as As­traZeneca lines up their $39B buy­out?

It looks like As­traZeneca may have a bonus wait­ing once it’s done ac­quir­ing Alex­ion.

Yes­ter­day, Rhythm Phar­ma­ceu­ti­cals put out word that the biotech sold their new­ly won pri­or­i­ty re­view vouch­er for $100 mil­lion — but with­out iden­ti­fy­ing the buy­er. And then, af­ter the mar­ket close, we found out in an SEC fil­ing that the mys­tery buy­er was Alex­ion.

Alex­ion has been scoop­ing up new ap­provals for its Soliris suc­ces­sor, Ul­tomiris, with an emer­gency Phase III un­der­way for Covid-19. But there’s not a lot of new drugs in the late-stage pipeline lin­ing up for a run at a quick OK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER